Aquestive Therapeutics Inc [AQST] stock is trading at $3.66, up 3.98%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AQST shares have gain 5.78% over the last week, with a monthly amount drifted -23.91%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Aquestive Therapeutics Inc [NASDAQ: AQST] stock has seen the most recent analyst activity on December 17, 2024, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $17. Previously, Leerink Partners started tracking the stock with Outperform rating on May 10, 2024, and set its price target to $8. On April 11, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $10 on the stock. Raymond James started tracking the stock assigning a Outperform rating and suggested a price target of $7 on March 28, 2024. In a note dated January 03, 2019, Lake Street initiated an Buy rating and provided a target price of $14 on this stock.
Aquestive Therapeutics Inc [AQST] stock has fluctuated between $1.95 and $6.23 over the past year. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Aquestive Therapeutics Inc [NASDAQ: AQST] shares were valued at $3.66 at the most recent close of the market. An investor can expect a potential return of 173.22% based on the average AQST price forecast.
Analyzing the AQST fundamentals
Aquestive Therapeutics Inc [NASDAQ:AQST] reported sales of 58.90M for the trailing twelve months, which represents a growth of 4.15%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.36%, Pretax Profit Margin comes in at -0.6%, and Net Profit Margin reading is -0.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is 0.63 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.53 points at the first support level, and at 3.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.72, and for the 2nd resistance point, it is at 3.79.
Ratios To Look Out For
For context, Aquestive Therapeutics Inc’s Current Ratio is 6.37. As well, the Quick Ratio is 5.91, while the Cash Ratio is 5.14. Considering the valuation of this stock, the price to sales ratio is 5.67.
Transactions by insiders
Recent insider trading involved Jung Cassie, Chief Operating Officer, that happened on Nov 26 ’24 when 44.0 shares were sold. Chief Innovation/Tech Officer, Schobel Alexander Mark completed a deal on Mar 15 ’24 to sell 50000.0 shares. Meanwhile, Chief Innovation/Tech Officer Schobel Alexander Mark sold 25000.0 shares on Mar 08 ’24.
